INTRODUCTION
Most human tumors are aneuploid. In about one-third of tumors, aneuploidy is preceded by a wholegenome doubling (WGD) (Zack et al., 2013) , an event that correlates with poor prognosis for patients (Bielski et al., 2018) . After WGD, the newly tetraploid genome promotes the evolution of aneuploid karyotypes (Dewhurst et al., 2014) , with tumor cells losing chromosomes and acquiring chromosomal rearrangements (Carter et al., 2012; Zack et al., 2013) . However, WGD can be detrimental to subsequent mitoses because centrosome number doubles (from two to four) concomitantly with genome doubling. During mitosis, each centrosome nucleates microtubules (Ring et al., 1982) , to form a multipolar spindle, which if uncorrected, can result in a lethal multipolar cell division (Ganem et al., 2009) . Alternatively, cells can cluster supernumerary centrosomes into two spindle poles, to allow the formation of a pseudo-bipolar spindle (Quintyne et al., 2005) , which permits bipolar cell division and survival. Given that centrosome amplification is common in cancers (Chan, 2011) and lethal multipolar cell divisions are expected to decrease the fitness of a tumor cell population, cancer cells likely experience selective pressures to efficiently cluster supernumerary centrosomes.
Human cells have an intrinsic ability to cluster centrosomes. This depends on proteins that directly or indirectly contribute to force generation during mitosis. Within the spindle, centrosome clustering arises from motor proteins located near spindle poles and centrosomes, such as dynein and KIFC1/HSET, as well as proteins localized at the kinetochore or centromere that control microtubule binding and spindle assembly checkpoint signaling (Drosopoulos et al., 2014; Kwon et al., 2008; Leber et al., 2010; Quintyne et al., 2005) . Outside of the spindle, at the cell cortex, motor proteins associated with the cortical actin network, such as Myo10 and dynein, position centrosomes by generating force on astral microtubules (Kwon et al., 2015; Quintyne et al., 2005) . Compared with non-transformed cells, centrosome clustering is more efficient in cancer cells (Ganem et al., 2009) . Although centrosome clustering efficiency can be increased by depletion of the microtubule-binding protein NUMA (Quintyne et al., 2005) or the adhesion protein E-cadherin (Rhys et al., 2018) , it remains largely unclear how cancer cells evolve to cluster centrosomes more proficiently.
Genomic analyses have identified genetic alterations that positively correlate with WGD (Bielski et al., 2018; Zack et al., 2013) . Several changes (TP53 and RB1 mutation, CCNE1 amplification) enable cell proliferation after WGD by alleviating the G1 arrest triggered after cytokinesis failure (Andreassen et al., 2001) . The molecular impact of other genetic changes that positively correlate with WGD, including alterations in protein phosphatase 2A (PP2A), is unknown. PP2A is a major source of serine/threonine phosphatase activity in eukaryotic cells. In the PP2A heterotrimer, a catalytic subunit (PP2A-Ca/b) and a ''scaffolding'' subunit (PP2A-Aa/b) are targeted to substrates by four evolutionarily conserved families of regulatory subunits. PP2A inactivation has been previously linked to tumorigenesis with the discovery that the SV40 small t antigen blocks the binding of PP2A-Aa/b to regulatory subunits (Pallas et al., 1990) , leading to cellular transformation (Chen et al., 2004) . Potentially similar perturbations in PP2A have been found to positively correlate with WGD in tumors. These include homozygous deletion of PPP2R2A, which encodes the B55a regulatory subunit, and heterozygous missense mutations in PPP2R1A, which encodes the a isoform of the scaffolding subunit PP2A-A, that accounts for $90% of total PP2A-A (Zhou et al., 2003) . Hotspot mutations in PP2A-Aa are expected to prevent B55 and B56 regulatory subunit binding (Cho and Xu, 2007; Xu et al., 2006 Xu et al., , 2008 and thus likely decrease the functionality of PP2A-Aa. Indeed, functional inactivation of PP2A by a recurrent P179R mutation in PPP2R1A has been recently implicated as a driver of tumorigenesis in highgrade endometrial carcinoma (Taylor et al., 2019) . In other studies, over-expression of certain hotspot PP2A-Aa mutants in tissue culture cells has been observed to alter phospho-signaling (Haesen et al., 2016; Jeong et al., 2016) . However, the impact of PP2A-Aa missense mutations with respect to WGD has not been examined.
Here we examine the impact of two prevalent hotspot mutations in PPP2R1A, P179R and R183W, on PP2A holoenzyme assembly and find that a reduction in protein-protein interactions predominates and is shared between the two mutants. We then focus on the P179R mutation in PPP2R1A, as this mutation is linked to tumorigenesis (Taylor et al., 2019) . When introduced into one allele of endogenous PPP2R1A, the P179R mutation reduces PP2A holoenzyme assembly and intracellular targeting of PP2A B56 in mitosis. Strikingly, we find that these changes are sufficient to increase centrosome clustering after WGD, possibly in part through factors at the cell cortex that position centrosomes. Moreover, overexpression of wild-type PP2A-Aa partially rescues centrosome clustering, suggesting that this phenotype arises from a decrease in PP2A activity in mitosis.
RESULTS

Characterization of Prevalent Cancer-Associated PP2A-Aa Missense Mutations
PPP2R1A is most frequently mutated in uterine cancers ( Figure 1A ), and to explore the cellular impact of the two most frequent PPP2R1A missense mutations ( Figure 1B ), we generated retinal pigment epithelial (RPE-1) hTERT cell lines expressing GFP-tagged PP2A-Aa wild-type (WT), P179R, or R183W. Each construct was expressed at 30%-40% of the level of endogenous PP2A-Aa/b ( Figure 1C ). Using quantitative mass spectrometry, we compared the composition of PP2A complexes isolated from stable isotope labeling by amino acids in cell culture (SILAC)-labeled cells by immunoprecipitation of WT or mutant GFP-PP2A-Aa. The P179R mutation significantly reduced PP2A-Aa binding to four B56 regulatory subunits (B56a/ PPP2R5A, B56b/PPP2R5B, B56d/PPP2R5D, and B56ε/PPP2R5E). Accordingly, the binding of proteins that associate with PP2A-Aa via B56 subunits including GEF-H1 (ARHGEF2), Liprina1 (PPFIA1) (Hertz et al., 2016) , and MTCL1 (Hyodo et al., 2016) was similarly reduced ( Figure 1D ). The P179R mutation also significantly reduced binding to the B55d/PPP2R2D regulatory subunit ( Figure 1D ). The binding of STRN regulatory subunits (STRN, STRN3, and STRN4), a B 00 regulatory subunit (PPP2R3A), and PP2A-C (PPP2CA, PPP2CB) was unaffected ( Figure 1D ). The R183W mutant had an overall similar decrease in protein-protein interactions ( Figure 1E ). Notably, although several proteins were observed to have increased binding to a PP2A-Aa mutant, none were shared between the two mutants ( Figure 1F ). Thus the major impact of both P179R and R183W mutations is to reduce protein-protein interactions.
A Heterozygous P179R Mutation in PP2A-Aa Impacts PP2A Holoenzyme Assembly in Human Cells
To examine if a heterozygous PP2A-Aa missense mutation is sufficient to impact PP2A functionality, we introduced a P179R mutation into one allele of endogenous PPP2R1A in RPE-1 cells. The P179R mutation was selected because it is the most prevalent missense mutation in uterine tumors, which have the highest incidence of PP2A-Aa alterations . We used adeno-associated virus-mediated gene targeting to introduce a C to G mutation in exon five of PPP2R1A ( Figure 2A ) and isolated two independent heterozygous clones ( Figure 2B ). The mutation did not alter the levels of PP2A-Aa or PP2A-Aa/b ( Figure 2C) . Similarly, PP2A-Aa immunoprecipitates from WT and PP2A-Aa P179R/+ cells had equivalent levels of PP2A-C ( Figure S1A ) and phosphatase activity ( Figure S1B ). By contrast, we observed near-2-fold reductions in PP2A-Aa association with B56g, d, and ε ( Figures 2D, 2E , and S1C) and B55a (Figures S1D and S1E). Consistent with a decrease in PP2A B56 holoenzyme levels, intracellular targeting of both PP2A-Aa and B56a to the centromere or kinetochore was reduced in PP2A-Aa P179R/+ cells (Figures 2F and 2G) . Collectively, these results indicate that a heterozygous P179R mutation in PP2A-Aa is sufficient to alter the level of a subset of PP2A holoenzymes.
PP2A-Aa P179R/+ Cells Suppress Multipolar Cell Division after Cytokinesis Failure
PPP2R1A mutations are enriched in tumors that experience WGD (Zack et al., 2013) . Given that the levels of PP2A B55 and PP2A B56 holoenzymes were reduced in PP2A-Aa P179R/+ cells, and that each of these holoenzyme families contribute to cell division (Craney et al., 2016; Espert et al., 2014; Kitajima et al., 2006; Lee et al., 2017; Schmitz et al., 2010) , we considered the possibility that the P179R mutation in PPP2R1A might impact cells in mitosis following WGD. To test this, we induced one round of cytokinesis failure (Yang et al., 2008) by treating cells with cytochalasin D or B, inhibitors of actin polymerization (Cooper, 1987) , or with blebbistatin, a myosin II inhibitor (Straight et al., 2003) . Binucleate cells were imaged live during the ensuing mitosis ( Figure 3A ). To avoid a G1 cell-cycle arrest triggered by cytokinesis failure (Andreassen et al., 2001) , we treated Tp53 +/+ cells with p38 inhibitor SB 203580 (Cuenda et al., 1995) or utilized Tp53 À/À cells. Almost 30% of WT cells treated with cytochalasin D underwent multipolar cell divisions. Strikingly, PP2A-Aa P179R/+ cells exhibited 4-fold reduction in the frequency of multipolar cell divisions compared with WT cells (7% in clone a and 8% in clone b) ( Figures 3B and 3C ). PP2A-Aa P179R/+ cells also underwent fewer multipolar cell divisions when cytokinesis failure was induced with cytochalasin B or blebbistatin ( Figure 3C ). Similar results were observed in Tp53 À/À PP2A-Aa P179R/+ cells ( Figure 3D ). Notably, whereas the expression of PP2A-Aa -P179R in WT cells had no impact on the outcome of cell division, the expression of GFP-PP2A-Aa-WT in PP2A-Aa P179R/+ cells partially rescued the cell division phenotype (Figures 3E and 3F) , suggesting that the observed phenotype is likely due to haploinsufficiency. . (C) Western blot analysis of cells expressing GFP-PP2Aa-WT or indicated mutants. Solid line indicates intervening lanes have been removed. (D and E) GFP immunoprecipitates from isotopically labeled RPE-1 cells expressing GFP-PP2A-Aa (WT, P179R, or R183W) were analyzed by mass spectrometry. Volcano plots with the mean log 2 fold-change of proteins bound to mutant versus GFP-PP2Aa-WT against -log 10 p value. 2-fold change (vertical dashed lines); p < 0.05 (horizontal dashed lines); red and blue circles indicate PP2A regulatory and catalytic subunits respectively. (F) Heatmap of proteins with significant changes in association. Green to red gradient represents the mean log 2 foldchange. X, protein not detected.
Given that PP2A-Aa P179R/+ cells have a modest delay in mitosis (22 min in clone a and 21 min in clone b versus 18 min in WT cells) ( Figure S2A ) and increased time spent in mitosis suppresses multipolar mitoses (Kwon et al., 2008) , we next compared the mitotic duration of binucleate cells that underwent a bipolar cell division. Both WT and PP2A-Aa P179R/+ cells completed mitosis with indistinguishable kinetics ( Figure 3G ). We also examined if the cell division phenotype was caused by centrosome inactivation as observed in Drosophila (Basto et al., 2008) . However, microtubule nucleation was observed at all centrosomes in WT and PP2A-Aa P179R/+ cells ( Figure S2B ). Moreover, in PP2A-Aa P179R/+ cells, centrosomes were always associated with spindle poles ( Figure S2C ) and were more likely to be clustered ( Figure S2D ). Our data suggest that enhanced bipolar cell division after WGD in PP2A-Aa P179R/+ cells is likely due to more efficient centrosome clustering and not due to centrosome inactivation or lengthening of mitosis.
PP2A-Aa P179R/+ Cells Cluster Supernumerary Centrosomes More Efficiently
To test the hypothesis that PP2A-Aa P179R/+ cells may cluster supernumerary centrosomes more efficiently than WT cells, centrosome amplification was induced by over-expression of Plk4 kinase Figure 4A ). This increases centrosome number without altering ploidy. We introduced a doxycycline-inducible Plk4 into Tp53 À/À WT and PP2A-Aa P179R/+ cells. After doxycycline induction, immunofluorescence analyses of C-Nap1, a marker of functional centrioles (Wang et al., 2011) , indicated that 64% of WT cells and 68% of PP2A-Aa P179R/+ cells had centrosome amplification (Figures S2E and S2F) . Immunofluorescence analysis of anaphase cells with extra centrosomes revealed that PP2A-Aa P179R/+ cells clustered centrosomes into a bipolar spindle more efficiently than WT cells, with a 6-fold reduction in multipolar anaphases (Figures 4B and 4C) . A similar result was observed by live imaging (Figures 4D and 4E) , with no delay in mitosis ( Figure 4F ).
Next, to examine how PP2A-Aa P179R/+ cells cluster centrosomes more efficiently, we asked if microtubule organization in mitosis is more robust in PP2A-Aa P179R/+ cells. Although centrosomes are the major sites of microtubule nucleation, a bipolar spindle can assemble in the absence of one or both centrosomes, albeit with some delay (Khodjakov et al., 2000) . We generated acentrosomal cells using centrinone, a small-molecule inhibitor of Plk4 (Wong et al., 2015) and measured the time between nuclear envelope breakdown and anaphase onset by live imaging. WT and PP2A-Aa P179R/+ cells were similarly delayed upon centrinone treatment ( Figures S2G and S2H) , indicating that spindle assembly is not more robust in acentrosomal PP2A-Aa P179R/+ cells. Spindle positioning and centrosome clustering in mitosis depends on cortical forces and interphase cell shape (Kwon et al., 2015; Rhys et al., 2018; Thé ry et al., 2005) . To examine the contribution of cortical forces to spindle positioning, cells were plated on L-shaped fibronectin micro-patterned coverslips. Spindle positioning was not impaired in PP2A-Aa P179R/+ cells with two centrosomes ( Figures  S2I-S2K ). We next examined the contribution of cortical forces and interphase cell shape to centrosome clustering in PP2A-Aa P179R/+ cells. Centrosome amplification was induced by Plk4 overexpression and cells plated onto O-or Y-shaped fibronectin micro-patterns ( Figure 4G, S2L, and S2M ). Both shapes bias cells with supernumerary centrosomes toward multipolar cell divisions (Kwon et al., 2008) . Indeed, in WT cells these patterns resulted in 1.8-fold and 1.6-fold increases in the frequency of multipolar cell divisions on O-and Y-shaped patterns, respectively ( Figure 4H ). Interestingly, in PP2A-Aa P179R/+ cells the frequency of multipolar cell divisions was increased by 2.6-and 3.9-fold on O-and Y-shaped patterns, respectively ( Figure 4H ). Thus, centrosome clustering efficiency in PP2A-Aa P179R/+ cells is more sensitive to interphase cell shape compared with WT cells. However, the overall frequency of multipolar cell divisions in PP2A-Aa P179R/+ cells was still reduced compared with WT cells ( Figure 4H ) suggesting that although cortical forces contribute to enhanced centrosome clustering in PP2A-Aa P179R/+ cells, the phenotype likely also arises from mechanisms unrelated to cell shape.
DISCUSSION
Human tumors frequently have centrosome amplification (Chan, 2011) , and cancer cells tend to be more proficient at clustering supernumerary centrosomes (Ganem et al., 2009) . Thus, in addition to relying on the intrinsic centrosome clustering ability of cells (Drosopoulos et al., 2014; Kwon et al., 2008 Kwon et al., , 2015 Leber et al., 2010; Quintyne et al., 2005) , cancer cells may acquire mutations that improve clustering efficiency. Here we have characterized a hotspot P179R mutation in PP2A-Aa that allows cells to cluster supernumerary centrosomes more efficiently. This finding is important because cells with supernumerary centrosomes only survive mitosis if they cluster centrosomes (Ganem et al., 2009) . Our data suggest that a potential explanation for the enrichment of PPP2R1A mutations in tumors that experience WGD is to allow cells to survive the mitotic stress associated with centrosome amplification. Tolerance to WGD has been shown to confer chromosomal instability and promote tumor genome evolution and is linked to poor prognosis (Bielski et al., 2018; Dewhurst et al., 2014) . Therefore, cancer-associated mutations in PP2A-Aa could also serve as a prognostic marker of tumor progression and is in agreement with PPP2R1A being annotated as a cancer driver in gynecological tumors (Bailey et al., 2018) .
Our findings also highlight the importance of considering PP2A-Aa mutations in a context that closely resembles the genetic change in tumors and suggest that the enhanced centrosome clustering efficiency arises from haploinsufficiency in PP2A-Aa function. Interestingly, the reduction in PP2A functionality by the P179R mutation in PP2A-Aa has been identified as a driver of tumorigenesis in uterine cancers (Taylor et al., 2019) and is consistent with the known tumor suppressor role of PP2A (Pallas et al., 1990) . Therefore, if the primary impact of the mutation is to reduce PP2A-Aa functionality, then it is perhaps unexpected that missense mutations dominate the PPP2R1A mutational landscape rather than truncations. Considering the heterotrimeric structure of PP2A holoenzymes, it is possible that several essential functions of PP2A may still be fulfilled by the mutant PP2A-Aa, including association with the catalytic subunit and association with STRN regulatory subunits, neither of which was altered by the P179R or R183W mutation. Thus the mutations may selectively impact the subset of PP2A holoenzymes with tumor suppressor functions. Given that small-molecule activators of PP2A have been shown to reduce the tumorigenicity associated with PP2A inactivation by the P179R mutation (Taylor et al., 2019) , it will be important to further investigate the anti-tumor efficacies of pharmacologic activators of PP2A (Ramaswamy et al., 2015; Sangodkar et al., 2017) in human cancers with other oncogenic PP2A mutations.
Furthermore, our work reveals that decreasing PP2A functionality increases centrosome clustering. This observation together with the identification of a role for PP2A-B55/SUR-6 in regulating centrosome separation during mitotic entry (Boudreau et al., 2019) opens new avenues of exploration for a role of PP2A in the regulation of centrosome clustering. Our data also suggest that fine-tuning phosphoregulation, in the form of a heterozygous PP2A-Aa mutation, allows a human cell to become more proficient at centrosome clustering without compromising mitotic fidelity. Because the mutation only partially reduces PP2A-Aa function, and a WT allele remains present in the cell, we predict that the observed phenotype is due to small changes in phosphorylation of substrates that impact centrosome positioning and engagement during mitosis. Therefore, future work will focus on characterizing phosphorylation sites that control centrosome clustering in PP2A-Aa P179R/+ cells.
Limitations of the Study
One limitation of this study is that we examined the impact of PP2A-Aa mutations in a non-cancer cell line. The advantage of this choice is that we could determine that the mutation is sufficient to alter centrosome clustering, whereas the limitation is that we did not examine the mutation in a transformed cell. The other limitation is that we did not perform gene replacement for all PP2A-Aa isoforms, and therefore further studies are needed to determine if this effect on centrosome clustering is shared among other recurrent mutations.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.07.018.
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Contact for reagent and resource sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Emily A Foley (emilyafoley@gmail.com) .
Experimental model and subject details
RPE-1 hTERT (WT) cells (a gift from Alexey Khodjakov) and derivative cell lines were grown at 37°C in a humidified atmosphere with 5% CO2 in DMEM:F12 growth medium.
Human embryonic kidney 293-T cells (ATCC) and Human embryonic kidney 293 cells (ATCC) were grown in DMEM growth medium. All media were supplemented with 10% fetal bovine serum (VWR Life Science), penicillin-streptomycin (Gemini Bio-Products), non-essential amino acids (Life Technologies), and L-glutamine (Sigma-Aldrich). Cell lines were authenticated upon initial receipt and upon initial generation by Short Tandem Repeat analysis at the Integrated Genomics Operations at Memorial Sloan Kettering Cancer Center. Cell lines were also tested for mycoplasma contamination by the Antibody and Bioresource core facility at Memorial Sloan Kettering Cancer Center.
Cell line generation
To generate the PP2A-Aα P179R/+ cell lines, we used adeno-associated virus-mediated gene targeting. Q5 High-Fidelity DNA polymerase (New England Biolabs) was used to amplify two homology arms spanning exons 5 and 6 of PPP2R1A and cloned into a bacterial artificial chromosome (Life Technologies). The homology arms were cloned into vector pNX (Papi et al., 2005) flanking a loxP-Neo R -loxP cassette. Site-directed mutagenesis was used to introduce a C to G mutation at nucleotide 23280 in exon 5 of PPP2R1A. The PPP2R1A homology fragment was then cloned into pAAV by NotI restriction enzyme digestion. Isolation of AAV particles, selection of stable transductants, and PCR screening were carried out as previously described . We determined the PPP2R1A genotype in isolated clones by genomic PCR amplification of PPP2R1A followed by Sanger sequencing. We isolated two clones (termed a and b), each with a heterozygous PPP2R1A P179R mutation. For each clone, the neomycin cassette was excised by infecting cells with adenovirus expressing Cre recombinase (Vector Development Laboratory, Baylor College of Medicine) at a multiplicity of infection of 80 plaque-forming units/cell. We identified single clones that were negative for the neomycin cassette but positive for the remnant loxP site by PCR amplification of endogenous PPP2R1A. Clone a was used for all experiments and, where indicated, clone b was also examined.
To generate Tp53 knockout cell lines, codon-optimized Cas9 (Addgene 41815) and a guide RNA targeting Tp53 (Wang et al., 2015) were transfected into cells using a Nucleofector 2b Device (Lonza) with the setting T023. Colonies were screened for p53 loss by western blot using an antibody for the N-terminus of p53 (Santa Cruz Biotechnology SC-126, clone DO-1). To generate cell lines expressing tetracyclineinducible Plk4, we used the lentiviral pLVX-Tight-Puro system (Clontech). Lentiviruses were generated in HEK 293T cells transfected with psPAX2 (Addgene plasmid 12260), pCMV-VSV-G (Addgene plasmid 8454) and Plk4 cloned into pLVX-Tight-puro (Clontech) using Lipofectamine 2000 (Thermo Fisher Scientific) according to manufacturer's instructions. 48 h after transfection, the virus containing suspension from HEK293T cells was filtered with a 0.45 µM filter (EMD Millipore), supplemented with polybrene (4 μg/mL, Sigma) and applied to Tp53-knockout WT cells or PP2A-Aα P179R/+ cells. Cells were first transduced with Plk4 in pLVX-tight-puro lentivirus and selected with puromycin (15 µg/mL, Thermo Fisher Scientific) for 1 week. Puromycin-resistant cells were then grown in Tetracycline-free serum (Clontech) and transduced with pLVX-Tet-On-Advanced lentivirus followed by G418 selection (500 µg/mL, Thermo Fisher Scientific) for 1 week.
For each PP2A-Aα genotype, we chose a clone that yielded centrosome amplification in 60% of cells after 48 h doxycycline treatment (1 µg/mL).
We generated cells with fluorescent H2B by lentiviral transduction. H2B-RFP (Addgene plasmid 26001) or H2B-GFP (Addgene plasmid 25999) plasmids were co-transfected with psPAX2 and pCMV-VSV-G into HEK 293T cells. Supernatants were filtered, mixed with polybrene (4 μg/mL) and applied to target cells. We generated cells expressing GFP-PP2Aα by retroviral transduction as in using WT PP2A-Aα or P179R and R183W mutants, which were cloned via site-directed mutagenesis.
Inhibitor treatments
Commercially available small molecules and chemical inhibitors were used as followscytochalasin D (0.2 μM), cytochalasin B (4 µM 
Live-cell imaging
Live imaging was performed on a Nikon Eclipse TiE inverted microscope equipped with a PI Piezo stage controller and Nikon Perfect Focus. Cells were maintained at 37 °C and 5% CO2 with a Stage Top Incubator with Flow Control and a Sub Stage Environmental Enclosure (Tokai Hit). Cells were imaged by DIC and fluorescence microscopy (GFP-Ex470 nm; Em522 nm or DsRed-Ex508 nm; Em620 nm). Images were acquired with a 20X or 40X objective and recorded on a deep-cooled, ultra-low noise sCMOS camera (Andor) at 16-bit depth using Elements software (Nikon). Image cropping was performed in Fiji (Schindelin et al., 2012) .
Immunofluorescence microscopy
For immunofluorescence microscopy of α-tubulin, C-Nap 1, and centrin-1, cells on coverslips were fixed in methanol at −20 °C for 10 min. For PP2A-Aα and B56α
